Lincoln Pharmaceuticals Limited (BOM:531633)

Lincoln Pharmaceuticals Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	6,710	6,710	6,232	5,805	5,103	4,721
Revenue Growth	7.67%	7.67%	7.35%	13.76%	8.09%	11.30%
Gross Profit Gross Profit Growth	3,599	3,599	3,262	2,975	2,646	2,502
Operating Income Operating Income Growth	831.84	831.84	890.57	895.83	805.47	876.98
Net Income Net Income Growth	878.94	878.94	823.46	933.05	728.99	693.55
Earnings Per Share EPS Growth	43.88	43.88	41.11	46.58	36.40	34.63
EPS Growth	6.74%	6.74%	-11.74%	27.98%	5.11%	11.41%

Revenue by Geography

Chart

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
India India Growth	2,360	2,180	2,172	2,040
Rest of World Rest of World Growth	3,872	3,625	2,931	2,681
Total Total Growth	6,232	5,805	5,103	4,721

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	2,412	2,412	1,957	1,524	1,080	1,151
Total Debt Total Debt Growth	44.22	44.22	-	10.67	19.97	20.44
Net Cash (Debt) Net Cash Growth	2,368	2,368	1,957	1,514	1,060	1,131
Net Cash Growth	20.98%	20.98%	29.28%	42.76%	-6.22%	20.31%
Net Cash Per Share Net Cash Per Share Growth	118.21	118.21	97.71	75.58	52.94	56.46

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	1,064	1,064	930.16	632.17	392.62	761.32
Capital Expenditures CapEx Growth	-254.28	-254.28	-190.29	-394.76	-142.59	-455.25
Free Cash Flow Free Cash Flow Growth	809.31	809.31	739.86	237.41	250.03	306.07
Free Cash Flow Growth	9.39%	9.39%	211.64%	-5.05%	-18.31%	-49.43%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	53.63%	53.63%	52.34%	51.24%	51.84%	52.99%
Operating Margin	12.40%	12.40%	14.29%	15.43%	15.78%	18.57%
Pretax Margin	17.23%	17.23%	17.52%	21.06%	19.69%	20.32%
Profit Margin	13.10%	13.10%	13.21%	16.07%	14.29%	14.69%
FCF Margin	12.06%	12.06%	11.87%	4.09%	4.90%	6.48%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul 28, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Dividend Per Share Dividend Per Share Growth	1.800	1.800	1.800	1.800	1.500	1.500
Dividend Per Share Growth	0%	0%	0%	20.00%	0%	0%
Dividend Yield	0.31%	0.32%	0.33%	0.31%	0.45%	0.49%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul 28, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	13.23	12.86	13.42	12.57	9.31	8.98
Forward PE	-	7.52	7.52	7.52	7.52	7.52
P/FCF Ratio	14.37	13.97	14.93	49.39	27.13	20.36
PS Ratio	1.73	1.69	1.77	2.02	1.33	1.32

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 25, 2026

Data Sources Report a data error